GB9706294D0 - Heterocyclic compound - Google Patents

Heterocyclic compound

Info

Publication number
GB9706294D0
GB9706294D0 GBGB9706294.7A GB9706294A GB9706294D0 GB 9706294 D0 GB9706294 D0 GB 9706294D0 GB 9706294 A GB9706294 A GB 9706294A GB 9706294 D0 GB9706294 D0 GB 9706294D0
Authority
GB
United Kingdom
Prior art keywords
heterocyclic compound
heterocyclic
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9706294.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
Glaxo Wellcome SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome SpA filed Critical Glaxo Wellcome SpA
Priority to GBGB9706294.7A priority Critical patent/GB9706294D0/en
Publication of GB9706294D0 publication Critical patent/GB9706294D0/en
Priority to PCT/EP1998/001700 priority patent/WO1998042673A1/en
Priority to YU47699A priority patent/YU47699A/sh
Priority to KR1019997008630A priority patent/KR20010005567A/ko
Priority to CN98805302A priority patent/CN1257482A/zh
Priority to PL98335865A priority patent/PL335865A1/xx
Priority to EA199900755A priority patent/EA199900755A1/ru
Priority to HU0001661A priority patent/HUP0001661A3/hu
Priority to IL13191998A priority patent/IL131919A0/xx
Priority to NZ337793A priority patent/NZ337793A/en
Priority to APAP/P/1999/001659A priority patent/AP9901659A0/en
Priority to AU72094/98A priority patent/AU731394B2/en
Priority to JP54323498A priority patent/JP2001518901A/ja
Priority to BR9808424-0A priority patent/BR9808424A/pt
Priority to EP98919133A priority patent/EP0971896A1/en
Priority to CA002284710A priority patent/CA2284710A1/en
Priority to TR1999/02315T priority patent/TR199902315T2/xx
Priority to IDW991108A priority patent/ID24306A/id
Priority to IS5186A priority patent/IS5186A/is
Priority to NO994679A priority patent/NO994679L/no
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
GBGB9706294.7A 1997-03-26 1997-03-26 Heterocyclic compound Pending GB9706294D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB9706294.7A GB9706294D0 (en) 1997-03-26 1997-03-26 Heterocyclic compound
IDW991108A ID24306A (id) 1997-03-26 1998-03-24 Turunan asam kuinolin-2 karboksilat dan penggunaannya sebagai antagonis asam amino eksitatori
IL13191998A IL131919A0 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
APAP/P/1999/001659A AP9901659A0 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivatives and its use as excitatory amino acids antagonist.
KR1019997008630A KR20010005567A (ko) 1997-03-26 1998-03-24 퀴놀린-2-카르복실산 유도체 및 그의 흥분성 아미노산 길항제로서의 용도
CN98805302A CN1257482A (zh) 1997-03-26 1998-03-24 喹啉-2-羧酸衍生物及其作为兴奋性氨基酸拮抗剂的用途
PL98335865A PL335865A1 (en) 1997-03-26 1998-03-24 Derivative of quinoline-2-carboxylic acid and application thereof as an antagonist of stimulating amino acids
EA199900755A EA199900755A1 (ru) 1997-03-26 1998-03-24 Производное хинолин-2-карбоновой кислоты и его применение в качестве антагониста возбуждающих аминокислот
HU0001661A HUP0001661A3 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
PCT/EP1998/001700 WO1998042673A1 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
NZ337793A NZ337793A (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivatives and the use of these derivatives in the preparation of medicaments for antagonising the effect of excitatory amino acids upon the NMDA receptor complex
YU47699A YU47699A (sh) 1997-03-26 1998-03-24 Derivat hinolin -2-karboksilne kiseline i njegova upotreba kao antagonist ekscitatornih amino kiselina
AU72094/98A AU731394B2 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
JP54323498A JP2001518901A (ja) 1997-03-26 1998-03-24 キノリン−2−カルボン酸誘導体およびその興奮性アミノ酸拮抗薬としての使用
BR9808424-0A BR9808424A (pt) 1997-03-26 1998-03-24 Composto, processos para a preparação do mesmo, para a preparação dos intermediários e para tratamento de um mamìfero, incluindo o ser humano, composição farmacêutica, e, uso de um composto.
EP98919133A EP0971896A1 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
CA002284710A CA2284710A1 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
TR1999/02315T TR199902315T2 (xx) 1997-03-26 1998-03-24 Kuinolin-2-karboksilik asit ve uyar�c� amino asit antagonisti olarak kullan�m�.
IS5186A IS5186A (is) 1997-03-26 1999-09-17 Kínólín-2-karboxýlsýru afleiða og notkun hennar sem mótlyf fyrir örvandi amínósýrur
NO994679A NO994679L (no) 1997-03-26 1999-09-24 Quinolin-2-karboksylsyrederivat og anvendelse derav som eksitatorisk aminosyreantagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9706294.7A GB9706294D0 (en) 1997-03-26 1997-03-26 Heterocyclic compound

Publications (1)

Publication Number Publication Date
GB9706294D0 true GB9706294D0 (en) 1997-05-14

Family

ID=10809909

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9706294.7A Pending GB9706294D0 (en) 1997-03-26 1997-03-26 Heterocyclic compound

Country Status (20)

Country Link
EP (1) EP0971896A1 (no)
JP (1) JP2001518901A (no)
KR (1) KR20010005567A (no)
CN (1) CN1257482A (no)
AP (1) AP9901659A0 (no)
AU (1) AU731394B2 (no)
BR (1) BR9808424A (no)
CA (1) CA2284710A1 (no)
EA (1) EA199900755A1 (no)
GB (1) GB9706294D0 (no)
HU (1) HUP0001661A3 (no)
ID (1) ID24306A (no)
IL (1) IL131919A0 (no)
IS (1) IS5186A (no)
NO (1) NO994679L (no)
NZ (1) NZ337793A (no)
PL (1) PL335865A1 (no)
TR (1) TR199902315T2 (no)
WO (1) WO1998042673A1 (no)
YU (1) YU47699A (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
DE10137487A1 (de) * 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
DE10306202A1 (de) 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
JP4360891B2 (ja) 2003-12-09 2009-11-11 アルパイン株式会社 放送受信機能を備えた電子装置およびその装置における電子番組ガイドの表示方法
KR101136183B1 (ko) 2005-07-22 2012-04-17 모찌다 세이야쿠 가부시끼가이샤 신규 헤테로시클리덴 아세트아미드 유도체
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP7305560B2 (ja) 2017-06-12 2023-07-10 グリテック, エルエルシー Nmdaアンタゴニスト及びd2/5ht2a又は選択的5ht2aアンタゴニストによるうつ病の治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
TR199800531T1 (xx) * 1995-09-29 1998-06-22 Glaxo Wellcome Spa NMDA antagonistleri olarak tetrahidrokinolinler.
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds

Also Published As

Publication number Publication date
ID24306A (id) 2000-07-13
PL335865A1 (en) 2000-05-22
TR199902315T2 (xx) 2000-05-22
AP9901659A0 (en) 1999-09-30
HUP0001661A3 (en) 2001-12-28
NZ337793A (en) 2001-02-23
JP2001518901A (ja) 2001-10-16
NO994679L (no) 1999-11-24
WO1998042673A1 (en) 1998-10-01
IL131919A0 (en) 2001-03-19
AU7209498A (en) 1998-10-20
CN1257482A (zh) 2000-06-21
AU731394B2 (en) 2001-03-29
EP0971896A1 (en) 2000-01-19
KR20010005567A (ko) 2001-01-15
BR9808424A (pt) 2000-05-23
EA199900755A1 (ru) 2000-08-28
NO994679D0 (no) 1999-09-24
HUP0001661A2 (hu) 2000-09-28
YU47699A (sh) 2001-12-26
CA2284710A1 (en) 1998-10-01
IS5186A (is) 1999-09-17

Similar Documents

Publication Publication Date Title
EG24041A (en) New heterocyclic compounds
IL134086A0 (en) Novel spiroazabicyclic heterocyclic compounds
GB9715892D0 (en) Heterocyclic compounds
IL132170A0 (en) Novel heterocyclic compounds
GB9800575D0 (en) Heterocyclic compounds
GB9602294D0 (en) Heterocyclic compounds
GB9617305D0 (en) Heterocyclic compounds
ZA981920B (en) Novel heterocyclic compounds
GB9706294D0 (en) Heterocyclic compound
ZA985448B (en) Novel heterocyclic compounds
ZA983800B (en) Novel heterocyclic compounds
EP0900204A4 (en) HETEROCYCLIC CONNECTIONS
GB9706309D0 (en) Heterocyclic compound
EP0900217A4 (en) HETEROCYCLIC COMPOUNDS
EP0900219A4 (en) HETEROCYCLIC COMPOUNDS
EP0912183A4 (en) HETEROCYCLIC COMPOSITIONS
GB9404942D0 (en) Heterocyclic compound
GB9702945D0 (en) Heterocyclic compounds
GB9715734D0 (en) Heterocyclic compounds
ZA989421B (en) Heterocyclic compounds
GB9716378D0 (en) Heterocyclic compounds
GB9715735D0 (en) Heterocyclic compounds
GB9801058D0 (en) Heterocyclic compounds
ZA981177B (en) Heterocyclic compounds
GB9719237D0 (en) Heterocyclic compounds